TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: XM-One Study for Living Donor Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recipients receiving deceased donor transplants.~* Living donor transplant that is T-cell flow crossmatch positive.~* HIV, Hepatitis C and B positive patients.~Exclusion Criteria:~* Pregnant women and children will be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (ages 18-80) on PN with silicone-based central venous catheters~Exclusion Criteria:~* Weight ≤ 50 kg~* Allergy/hypersensitivity/intolerance to ethanol or heparin~* Pregnancy or breastfeeding~* Patient taking metronidazole, disulfiram, or isoniazid~* History of alcohol abuse~* History of heparin-induced thrombocytopenia (HIT) or have an active hypocoagulable state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ethanol lock (Type: ACTIVE_COMPARATOR): 70% ethanol
- Heparin lock (Type: ACTIVE_COMPARATOR): Heparinized saline (100 U/mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed HNSCC~* adequate primary site: oral cavity, oropharynx, hypopharynx, nasal cavity, paranasal sinus, other head and neck site (except nasopharynx)~* at least one measurable lesion~* no previous palliative chemotherapy (adjuvant/neoadjuvant chemotherapy and/or radiotherapy longer than 6 months ago is permitted)~* 18 years or older~* ECOG 0 or 1~* adequate laboratory result~* written, informed consent~Exclusion Criteria:~* pregnant or lactating women (negative pregnancy test within 7 days is required for women with potential of child-bearing)~* experimental drug clinical trial within 30 days~* other malignancy (exemption: treated basal cell carcinoma of skin, CIS, cured cancer with disease-free interval with more than 5 years)~* patient with organ transplantation~* grade 2 or more peripheral neuropathy~* grade 2 or more hearing loss~* severe, medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): docetaxel+CDDP
- 2 (Type: EXPERIMENTAL): docetaxel+S-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Speedlyte and IV Rehydration Treating Children With Gastroenteritis in a Pediatric Emergency Department (ED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6 mths to 18 years;~* Signs and symptoms of dehydration for less than a week~* Diagnosis of acute gastroenteritis, dehydration, vomiting, and/or diarrhea;~* Patient able to drink from bottle and/or cup;~* Per clinician's judgment, patient needs rehydration with IV solution.~Exclusion Criteria:~* Chronic disease that includes but not limited to TB, HIV, congenital heart disease with hemodynamic consequences, metabolic disease, cerebral palsy, adrenal hyperplasia, renal tubular acidosis, and nephropathy;~* Vomiting due to head trauma;~* Severe hydration;~* Diabetic ketoacidosis;~* Bloody diarrhea;~* Diarrhea for more than a week;~* Malnutrition;~* Burns;~* Pneumonia;~* Meningitis;~* History of seizures;~* Absent bowel sounds;~* Not able to drink from bottle or cup;~* Previous allergic reaction to citrate or other food coloring particles/formulation;~* Parent/legal guardian refusing to participate.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Standard IV Rehydration Therapy (Type: ACTIVE_COMPARATOR): Patients randomized into the IV rehydration group will receive a Normal Saline bolus of IVF (usually 20 mL/kg) which is the standard therapy up to 24 hrs or as needed depending on patient's weight
- Oral Rehydration Therapy (ORT) (Type: EXPERIMENTAL): Patients randomized into the oral rehydration group will receive the oral Speedlyte product instead of the IV rehydration therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Rectal Acetaminophen Use During Oocyte Retrievals to Reduce Post-Operative Opioid Utilization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any female patient undergoing oocyte retrieval by transvaginal ultrasound-guided ovarian puncture~Exclusion Criteria:~* Patients with chronic pain conditions such as fibromyalgia and sickle cell anemia.~* Patient with BMI greater than 40~* Patients that required general endotracheal intubation anesthesia in prior oocyte retrieval~* Patients with documented allergic reaction to acetaminophen~* Patient with contra-indication to the use of acetaminophen (liver disease)~* Patients with a history of past or current alcohol, drug or opioid abuse~* Patients with ulcerative colitis, Crohn's disease, or severe rectal hemorrhoids

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 56 Years
- Healthy Volunteers: t

Study Arms:
- Fentanyl/propofol + acetaminophen (Type: EXPERIMENTAL): In addition to the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol, one dose of 1300 mg of solid base rectal acetaminophen suppository (2 suppositories) will be administered at the end of oocyte retrieval.
- Fentanyl/propofol only (Type: ACTIVE_COMPARATOR): Participants in this arm will receive the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented GM1 gangliosidosis diagnosis based on genotyping confirming the β-gal gene mutations and/or documented deficiency of β-gal enzyme by laboratory testing~* Children with early infantile GM1 gangliosidosis less than 12 months of age with ability to swallow~* Children with late infantile GM1 gangliosidosis less than 3 years of age with ability to sit~Exclusion Criteria:~* Uncontrolled seizure disorder. Patients who are stable on anti-convulsive medications may be included~* More than 40% brain atrophy as measured by MRI total brain volume at screening~* Current participation in a clinical trial of another investigational medicinal product~* Past participation in a gene therapy trial~* History of hematopoietic stem cell transplantation~* Any condition that would contraindicate treatment with immunosuppressant therapy~* Presence of concomitant medical condition or anatomical abnormality precluding lumbar puncture or intracisternal injection~* Presence of any permanent items (e.g., metal braces) precluding undergoing MRI~* History of non-GM1 gangliosidosis medical condition that would confound scientific rigor or interpretation of results~* Rare and unrelated serious comorbidities, e.g., Down syndrome, intraventricular hemorrhage in the new-born period, extreme low birth weight (\<1500 grams) or known bleeding disorders~* Any vaccination 1 month prior to the planned immunosuppressant treatment~* Serology consistent with HIV exposure or consistent with active hepatitis B or C infection~* Grade 2 or higher lab abnormalities for Liver function tests (LFT), bilirubin, creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time (PT), and partial thromboplastin time (PTT), according to CTCAE v5.0

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- 8x10^12 vg/Kg LYS-GM101 (Type: EXPERIMENTAL): Subjects will receive a single infusion: 8x10\^12 vg/Kg LYS-GM101

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven incurable stage IV carcinoma of the uterine cervix and/or vulva that is unlikely to respond to existing therapy~* Measurable disease by MRI or CT scan~* Tumor must be at least 2 cm~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No known chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Not a high medical or psychiatric risk~* No concurrent nonmalignant systemic disease~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* At least 1 month since prior tamoxifen if no progression~  * May enter study immediately if evidence of progression~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplastons~* No other concurrent antineoplastic agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* good general health~* ≥18 years old~* seeking termination of a viable intrauterine pregnancy of ≤63 days, without any evidence of a threatened or spontaneous abortion~Exclusion Criteria:~* medical problems~* confirmed or suspected ectopic pregnancy~* having taken medications in the seven days prior to enrollment that would affect PG synthesis or metabolism of mifepristone

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): None
- Non-treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of App-based Relaxation for Patients With Chronic Low Back Pain (Relaxback)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female or male~* 18-65 years of age~* chronic low back pain for at least 12 weeks~* if additional back pain is reported, low back pain has to be predominant~* intensity of the average low back pain ≥ 4 on the numeric rating scale (NRS) in the last week~* presence of a smartphone (iphone, Android phone) and willingness to do data entry through a smart phone application (App)~* willingness to be randomized, to apply study intervention according to the protocol, to complete the baseline questionnaire in paper form and electronic questionnaires and diaries provided by an App physical and mental ability to participate in the study~* written and oral informed consent~Exclusion Criteria:~* low back pain caused by a known malignant disease~* neck pain caused by trauma~* known rheumatic disorder~* history or planned surgery of the spinal column of the low back in the next 6 months~* known neurological symptoms e.g radicular symptoms because of prolapsed vertebral disc~* regular intake of analgesics (\>1x per week) because of additional diseases~* intake of centrally acting analgesics~* known severe acute or chronic disorder, that do not allow participation in the therapy~* other known diseases, that do not allow participation in the therapy~* known alcohol or substance abuse~* no sufficient German language skills~* current application for a benefit~* participation in another clinical trial during six months before the study and parallel to the study~* conducting regular relaxation techniques, mindfulness training or meditation six weeks before the study or planned in the next 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- relaxation (Type: EXPERIMENTAL): Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
- Usual care waiting list (Type: ACTIVE_COMPARATOR): Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2 -18 years;~* Previous history of asthma;~* Hospital admission for acute asthma exacerbation;~* Clinical asthma score greater than or equal to 3~Exclusion Criteria:~* Less than 2 years old or over 18 years old;~* Known allergy or hypersensitivity to ß-agonists;~* Require mechanical ventilation (invasive or non-invasive);~* Require FiO2 \>0.4;~* Failure to obtain informed consent;~* Enrollment in another investigational drug or asthma protocol;~* Incipient respiratory failure including but limited to respiratory acidosis(pCO2\>60 torr), altered mental status and/or excessive work of breathing.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Heliox-powered albuterol) (Type: EXPERIMENTAL): Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.
- Group 2 (Oxygen-powered albuterol) (Type: ACTIVE_COMPARATOR): Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Identification of Key Blood Molecular Markers for Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with cancerous tumors based on biopsy or other clinical observations.~2. Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations.~3. Normal volunteers who do not have cancer or other medical conditions that may affect survival.~Exclusion Criteria:~1. Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors.~2. Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings may be altered.~3. Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intraurethral Lidocaine After Endourology Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Adult patients, age 18 and older scheduled to undergo endourologic procedure to include ureteroscopy, rigid diagnostic cystoscopy, bladder biopsy, laser lithotripsy, cystolithalopaxy, and transurethral resection of bladder tumor in the operating room under general anesthesia.~-~Exclusion Criteria: active urinary tract infection, current dysuria symptoms, pregnant females, urethral stricture disease, indwelling foley catheter, and history of pelvic radiation~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Experiment (Type: EXPERIMENTAL): Lidocaine jelly (2%) 5mL x 1 dose only
- Placebo (Type: PLACEBO_COMPARATOR): Surgilube 5mL x 1 dose only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Esophagectomy With or Without Prior Ischemic Gastric Preconditioning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is willing and able to provide written informed consent~* Subject is a candidate for esophagectomy with or without gastric pre-conditioning procedure per thoracic surgeon~* Patient is at least 18 years old~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Cancer stage: T1-2-3 N0M0, Locally advanced, T2-3 N1M0 based on American Joint Committee on Cancer (AJCC) 7th Edition by the oncologist~* No definitive radiological evidence of distant metastases as evaluated by CT or PET/CT scan~* Subject is willing and able to comply with the study procedures and complete the entire study as specified in the protocol, including follow-up visits.~Exclusion Criteria:~* Patients \< 18 years old~* History of invasive cancer within the past 5 years, (exceptions: non melanoma skin cancer, in situ cancers)~* Prior upper abdominal surgeries performed open and/or laparoscopic; such as but not limited to Nissen fundoplication, gastrectomy, bariatric surgery, hiatus hernia repair.~* Subject is participating in another investigational trial~* Subject is pregnant or has plans to become pregnant during the study period or is currently breastfeeding~* Subject is part of the site personnel directly involved with this study~* Subject is a family member of the investigational study staff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Two Stage Esophagectomy (Type: ACTIVE_COMPARATOR): Ischemic gastric preconditioning performed 7-10 prior to esophagectomy
- One Stage Esophagectomy (Type: ACTIVE_COMPARATOR): Esophagectomy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy